ReElement Technologies stock soars after securing $1.4B government deal
ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a pharmaceutical company showing strong momentum with a 56.8% price return over the past six months according to InvestingPro data, announced Wednesday it has filed a provisional patent application with the U.S. Patent and Trademark Office to strengthen intellectual property protection for its AVERSA™ abuse deterrent transdermal technology.
The application covers improved aversive formulations and coating application methods designed to enhance abuse deterrent properties of the company’s transdermal technology for patches containing opioids and stimulants.
If converted to a non-provisional application and granted, the patent could extend protection for products using the AVERSA™ technology for up to 20 years from the non-provisional filing date.
The AVERSA™ technology incorporates aversive agents into transdermal patches to deter oral abuse and reduce accidental exposure of drugs with abuse potential. The technology is currently protected by patents in 46 countries including the United States, Europe, Japan, and China.
According to the press release statement, the technology aims to improve safety profiles of transdermal drugs susceptible to abuse while maintaining accessibility for patients who need them.
Nutriband, which trades on the Nasdaq with a market capitalization of $94.93 million, is primarily focused on developing transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl patch incorporating the AVERSA™ technology. While the company posted impressive revenue growth of 42.92% in the last twelve months, InvestingPro analysis suggests the stock may be undervalued, with additional insights available to subscribers.
In other recent news, Nutriband Inc. reported a significant 50.87% year-over-year revenue increase for the first half of 2025, totaling $1,289,884. The company also disclosed that the exercise of stock options and warrants between February and July 2025 generated gross proceeds of approximately $5.35 million. Additionally, the U.S. Food and Drug Administration (FDA) has granted Nutriband a Type C Meeting to discuss its AVERSA FENTANYL abuse-deterrent transdermal system, with a virtual meeting scheduled for September 18, 2025. This meeting will provide feedback on the Chemistry, Manufacturing, and Controls plans for the product. Nutriband has also announced a preferred stock dividend, where shareholders of record on July 25, 2025, will receive one preferred share for every four common shares held, with distribution set for August 5. Each preferred share will be convertible to one common share following FDA approval of the AVERSA Fentanyl product. The company’s financial position includes $6.9 million in cash reserves as of July 31, 2025, with total assets of $10.17 million and stockholders’ equity of $8.5 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.